Castle Biosciences Q2 2024 GAAP EPS $0.31 Beats $(0.28) Estimate, Sales $87.002M Beat $69.341M Estimate
Portfolio Pulse from Benzinga Newsdesk
Castle Biosciences (NASDAQ:CSTL) reported Q2 2024 GAAP EPS of $0.31, significantly beating the analyst estimate of $(0.28). The company also reported sales of $87.002 million, surpassing the estimate of $69.341 million and marking a 73.53% increase from the same period last year.
August 05, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Castle Biosciences reported Q2 2024 GAAP EPS of $0.31, beating the analyst estimate of $(0.28) by 210.71%. The company also reported sales of $87.002 million, surpassing the estimate of $69.341 million and marking a 73.53% increase from the same period last year.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, is likely to positively impact CSTL's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100